The peptide boom: what The Atlantic got right — and where the story gets more complicated

For laboratory and research use only.

The Atlantic published a feature today on the underground peptide market — part of the wave of mainstream coverage that’s followed the GLP-1 boom and the broader emergence of peptide compounds in public conversation. It’s serious journalism. It deserves a serious response: one that engages with what it got right, pushes back where it overgeneralises, and supplies the context that tends to disappear in feature-length narratives.

The short version: the supply chain problems The Atlantic describes are real. The conflation of all peptide use with the grey-market bodybuilding corner of that use is not.

What the piece got right

Quality in the unregulated market

The strongest part of the article is its treatment of product quality. A significant chunk of peptides sold online — through channels with no regulatory oversight, no documentation requirements, no quality control obligations whatsoever — are simply not what they claim to be. The Atlantic is right about this.

Independent third-party analysis of products sold through various online markets has found mislabelled products (one peptide sold as another, or as a mixture), underdosing, contamination from bacterial endotoxins and residual solvents, and degraded product resulting from bad synthesis or improper storage. A 2017 JAMA Internal Medicine analysis of compounded hormone products found substantial deviation from labelled potency in a meaningful share of samples. That study focused on hormones rather than research peptides specifically, but the manufacturing challenges are comparable — and oversight in the research peptide space is, if anything, weaker.

None of this is fringe concern territory. Supply chain integrity matters enormously for research outcomes and for harm reduction for anyone obtaining peptides through informal channels. The Atlantic’s instinct to focus here was correct.

The grey market exists and is substantial

The piece also correctly identifies the large informal market operating in a legal grey area — where “research use only” labels serve as cover for products that are, in practice, being bought for personal use. The disconnect between formal classification and actual use patterns is real and well-known to anyone working in this space. On this point, the article is accurate.

Where it gets more complicated

Not all peptide use is the same

Here’s where the framing starts to break down. The Atlantic treats the underground bodybuilding market and academic or institutional research as parts of the same continuum. They aren’t remotely the same thing.

Academic institutions purchasing research-grade compounds from certified suppliers — under institutional procurement processes, for use in cell culture, animal studies, or assay development — operate within a completely different framework. There’s institutional oversight. IRB requirements for anything human-adjacent. Purchasing policies that require documented supplier credentials. This is not the same activity as ordering vials from a forum and self-injecting. Treating them as equivalent because both technically involve peptides is like treating hospital-grade morphine and street fentanyl as the same supply chain problem because both involve opioids.

The “research use only” classification exists for a specific legal and regulatory reason. Under US federal law, compounds that are neither approved drugs nor approved for use in food-producing animals can be sold for research without triggering the full drug approval pathway — provided they’re labelled for research purposes and not intended for human or veterinary therapeutic use. This isn’t a technicality designed to circumvent regulation. It’s the mechanism by which the broader scientific community, including pharmaceutical companies that eventually file INDs, accesses novel compounds for preclinical work.

The category becomes problematic when it’s misused as a retail channel for products functionally intended for personal use. That misuse is real. It doesn’t define the category.

What “research use only” actually means

Some precision here is useful, because loose usage on both sides creates confusion.

What the label means: the product is a research chemical, intended for laboratory use, not for therapeutic administration. The supplier makes no medical claims. The buyer is expected to be a qualified researcher using the compound in an appropriate research context.

What it doesn’t mean: that the compound has no scientific basis for research interest, that the preclinical literature doesn’t exist, or that the only people who want it are trying to get around regulations. Many compounds with substantial peer-reviewed preclinical literatures — BPC-157, TB-4 fragments, various neuropeptides — exist exclusively in the research-use category because no commercial sponsor has yet filed an IND to initiate clinical trials. That’s a function of economics and pharmaceutical prioritisation, not scientific illegitimacy.

Treating every research-use compound as inherently suspect because some are bought with non-research intent flattens a spectrum that has real gradations worth distinguishing.

The quality tiers the piece misses

The Atlantic implies, reasonably given its evidence, that quality in the peptide market is generally poor. This is true of the lower end. It’s not a description of the whole category.

The standards that separate credible research-grade suppliers from the grey market aren’t mysterious. Certificate of Analysis (COA) is the starting point — a documented analysis of the specific batch, including purity percentage, identity confirmation, and testing date. A COA from an in-house lab is less useful than one from an accredited third-party lab; any supplier that won’t share a third-party COA for a specific lot is telling you something.

HPLC (high-performance liquid chromatography) determines purity by separating the peptide from synthesis byproducts and measuring what proportion of the product is the desired compound. A credible HPLC report shows the actual chromatogram, not just a summary percentage. Mass spectrometry confirms molecular identity — the measured mass of the compound should match the theoretical mass of the peptide. Together, HPLC and MS provide meaningful assurance against substitution, degradation products, and mislabelling. Endotoxin testing rounds out the picture, checking for bacterial contamination using LAL assay or equivalent.

Suppliers who provide third-party COAs with both HPLC and MS data for each batch, maintain cold chain storage, and operate with traceable supply chains are doing something categorically different from operations that provide no documentation. The Atlantic’s piece doesn’t draw this distinction clearly, which matters — researchers need to know what to look for.

The regulatory picture in 2026

The regulatory environment is genuinely unsettled right now and it affects this whole conversation.

FDA enforcement against research peptide suppliers has been inconsistent. Actions have been taken against some operations, particularly those making explicit therapeutic claims or marketing directly to consumers with health benefit language. Many others operate without enforcement contact. The legal perimeter is fuzzy, and people operating within it know this.

The compounding pharmacy landscape adds a specific wrinkle. BPC-157 was placed on the FDA’s Category 2 bulk substances list in 2023, effectively prohibiting licensed compounding pharmacies from including it in preparations. HHS Secretary RFK Jr. has signalled interest in reviewing peptide scheduling and compounding restrictions, though as of this writing no formal action has been published. The practical effect of the 2023 classification has been to push demand that might have gone through licensed pharmacies — with at least some quality oversight — into less regulated channels. That’s not a good outcome from either a quality or safety standpoint, whatever your views on the underlying policy.

Worth monitoring closely if you work in this space.

The credibility problem

There’s a subtext in the Atlantic piece worth naming directly: the peptide field suffers from a credibility problem. Legitimate research gets tarred by association with unregulated self-experimentation and celebrity biohacker culture. This is fair.

I don’t think the response to that is to dismiss the entire category. The response is to be rigorous about evidence standards, transparent about what is and isn’t known, honest about what “research use only” actually means, and serious about quality at every point in the supply chain. Third-party COAs, HPLC, mass spectrometry, endotoxin testing, documented supply chains. Not aspirational. Baseline.

The Atlantic’s piece does a genuine service by drawing attention to the quality and safety gaps in the unregulated end of this market. It would do a more complete service by distinguishing between the parts of the market that have addressed those gaps and the parts that haven’t.

Good journalism about the peptide market is welcome. The quality and safety concerns are real, the grey-market ecosystem deserves scrutiny, and the piece raises questions worth engaging seriously. Where it falls short is in treating that ecosystem as representative of all research peptide activity — and in not adequately distinguishing between “research use only” as a regulatory category and as a retail loophole.

The questions are legitimate. The answers require more precision than the piece allows.

For laboratory and research use only.

Sources:
– Koren MJ et al., “Analysis of compounded bioidentical hormone preparations.” JAMA Internal Medicine, 2017.
– FDA Category 2 bulk substances list (BPC-157 classification, 2023).
– United States v. Caronia, 703 F.3d 149 (2d Cir. 2012) — context on research use labelling and speech.
– STAT News, “Inside the peptide underground.” (February 2026)
– The Atlantic, “The Peptide Boom.” (March 17, 2026)